These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23054689)

  • 1. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.
    Toovey S; Prinssen EP; Rayner CR; Thakrar BT; Dutkowski R; Koerner A; Chu T; Sirzen-Zelenskaya A; Britschgi M; Bansod S; Donner B
    Adv Ther; 2012 Oct; 29(10):826-48. PubMed ID: 23054689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
    Toovey S; Rayner C; Prinssen E; Chu T; Donner B; Thakrar B; Dutkowski R; Hoffmann G; Breidenbach A; Lindemann L; Carey E; Boak L; Gieschke R; Sacks S; Solsky J; Small I; Reddy D
    Drug Saf; 2008; 31(12):1097-114. PubMed ID: 19026027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.
    Smith JR; Sacks S
    Int J Clin Pract; 2009 Apr; 63(4):596-605. PubMed ID: 19335705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.
    Ueda N; Umetsu R; Abe J; Kato Y; Nakayama Y; Kato Z; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2015; 38(10):1638-44. PubMed ID: 26424023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study.
    Kang HR; Lee EK; Kim WJ; Shin JY
    J Antimicrob Chemother; 2019 Feb; 74(2):453-461. PubMed ID: 30418537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.
    L'Huillier AG; Ing Lorenzini K; Crisinel PA; Rebsamen MC; Fluss J; Korff CM; Barbe RP; Siegrist CA; Dayer P; Posfay-Barbe KM; Desmeules JA;
    Pharmacogenomics; 2011 Oct; 12(10):1493-501. PubMed ID: 21902503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study.
    Kang HR; Jang SC; Shin JY
    Expert Opin Drug Saf; 2021 Feb; 20(2):245-253. PubMed ID: 33183123
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010.
    Greene SK; Li L; Shay DK; Fry AM; Lee GM; Jacobsen SJ; Baxter R; Irving SA; Jackson ML; Naleway AL; Nordin JD; Narwaney KJ; Lieu TA
    Pharmacoepidemiol Drug Saf; 2013 Apr; 22(4):335-44. PubMed ID: 23129321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons.
    Blumentals WA; Song X
    MedGenMed; 2007 Oct; 9(4):23. PubMed ID: 18311373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oseltamivir and abnormal behaviors: true or not?
    Yorifuji T; Suzuki E; Tsuda T
    Epidemiology; 2009 Jul; 20(4):619-21. PubMed ID: 19367165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oseltamivir: cutaneous and neurological adverse effects in children.
    Prescrire Int; 2006 Oct; 15(85):182-3. PubMed ID: 17128526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study.
    Nordstrom BL; Oh K; Sacks ST; L'Italien GJ
    Antivir Ther; 2004 Apr; 9(2):187-95. PubMed ID: 15134180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health outcomes among patients receiving oseltamivir.
    Enger C; Nordstrom BL; Thakrar B; Sacks S; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):227-37. PubMed ID: 15255089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of Japanese infants younger than 3 months who were treated with oseltamivir for influenza: safety of oseltamivir treatment.
    Morioka I; Nonoyama S; Tanaka-Taya K; Ihara T; Sugaya N; Ueta I; Kumagai T; Okada K; Hosoya M; Okabe N; Morishima T;
    Scand J Infect Dis; 2012 Aug; 44(8):605-9. PubMed ID: 22497443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection.
    Tanabe T; Hara K; Nakajima M; Shimakawa S; Tamai H
    Brain Dev; 2010 Jun; 32(6):440-4. PubMed ID: 19200672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir: neuropsychiatric disorders.
    Prescrire Int; 2007 Oct; 16(91):200. PubMed ID: 17926837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir- related psychiatric manifestations.
    Guisado-Macías JA; Rodríguez FF; Méndez-Sánchez F; Bolívar-Perálvarez M
    Actas Esp Psiquiatr; 2012; 40(1):46-8. PubMed ID: 22344496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oseltamivir: new indication. Prevention of influenza in at-risk children: vaccination is best.
    Prescrire Int; 2007 Feb; 16(87):9-11. PubMed ID: 17323516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months.
    Rath BA; Blumentals WA; Miller MK; Starzyk K; Tetiurka B; Wollenhaupt M
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):286-96. PubMed ID: 25331369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.